Agoracom Blog Home

Archive for the ‘Innocan Pharma Corporation’ Category

« Older Entries
Newer Entries »

Innocan Pharma’s $INNO.ca Relief & Go #CBD Spray Successfully Passes Safety Assessments and is Approved for Marketing in the European Union $CGC.ca $APHA $OVAT.ca $KHRN.ca

Posted by AGORACOM-JC at 5:12 PM on Tuesday, October 27th, 2020
Innocan-Blog
  • R&G Relief & Go™ CBD Spray product has successfully passed the detailed safety assessment requirements under Regulation No 1223/2009 of The European Parliament and of the Council on Cosmetic Products and has received a Cosmetic Product Safety Report (“CPSR”) for product marketing in the European Union
  • “We are thrilled to receive another validation of our feasibility and to pass the EU regulation requirements for the marketing of our Relief & Go CPD Spray product”, says Iris Bincovich, Co-founder and CEO of Innocan, “This is a major accomplishment for our team and an exciting milestone of our future”.

Herzliya, Israel and Calgary, Alberta–(October 27, 2020) –  Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan”), is pleased to announce that its R&G Relief & Go™ CBD Spray product has successfully passed the detailed safety assessment requirements under Regulation No 1223/2009 of The European Parliament and of the Council on Cosmetic Products and has received a Cosmetic Product Safety Report (“CPSR”) for product marketing in the European Union.



Relief & Go

To view an enhanced version of this image, please visit:
https://orders.newsfilecorp.com/files/6922/66954_657f8b1b940c6910_002full.jpg

Innocan Israel, a wholly owned subsidiary of the Company, with its patent-pending unique formulation “Relief & Go CBD Spray” combines the known benefits of active ingredients such as Menthol and Camphor with CBD and Magnesium (more than 40% in the formula) to help the body relax and recover for sport-performing professionals. 

Innocan Israel’s CTO, Mr. Nir Avram has over 30 years of experience as a senior consultant in the area of pharmaceuticals and cosmetics. Nir consults in diverse areas of expertise including pharmaceutical and cosmetic innovations, generic formulations, and synthesis of novel materials, in connection with start-ups and established companies.

Nir is Vice President of Research & Development at Emilia Cosmetics Israel and Emilia Resources in the US. Prior to this he was VP of R&D at Careline, a leading cosmetics and toiletries manufacturer, and a member of the pharmaceutical innovation team at Perrigo.

“We are thrilled to receive another validation of our feasibility and to pass the EU regulation requirements for the marketing of our Relief & Go CPD Spray product”, says Iris Bincovich, Co-founder and CEO of Innocan, “This is a major accomplishment for our team and an exciting milestone of our future”.

About Innocan

Innocan Israel is a pharmaceutical tech company that focuses on the development of several drug delivery platforms containing CBD. Innocan Israel and Ramot at Tel Aviv University, are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 Corona Virus using CBD. CBD-Loaded Exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

Innocan Israel signed a worldwide exclusive license agreement with Yissum, the commercial arm of The Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection. Innocan Israel plans, together with Professor Berenholtz Head of the Laboratory of Membrane and Liposome Research of The Hebrew University of Jerusalem, to test the liposome platform on several potential indications. Innocan Israel is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for the relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan Israel each have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

Innocan Pharma Corporation
Iris Bincovich, CEO
+972-54-3012842
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable

Tags: , , , , , , , , , , , ,
Posted in Featured, Innocan Pharma Corporation | Comments Off on Innocan Pharma’s $INNO.ca Relief & Go #CBD Spray Successfully Passes Safety Assessments and is Approved for Marketing in the European Union $CGC.ca $APHA $OVAT.ca $KHRN.ca

Innocan Pharma $INNO.ca Announces the Publication of Two Studies Supporting Its CLX Therapy for COVID-19 Infected Lung Cells $IN.ca $AXIM $LABS $CRDL.ca $TBP.ca

Posted by AGORACOM-JC at 7:35 AM on Friday, October 23rd, 2020
Innocan-Blog
  • Announced the recent publication of two scientific articles supporting Innocan’s approach of using CBD-Loaded Exosomes (CLX) for the treatment of COVID-19
  • The first paper entitled, “Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patients” published in the Journal of Stem Cell Research & Therapy on October 15, 2020
  • study demonstrated that exosomes have the ability to enhance alveolar fluid clearance and promote epithelial and endothelial recovery through secretion of protective factors
  • The second paper entitled, “Cannabidiol (CBD) modulation of apelin in acute respiratory distress syndrome” published in the Journal of Cellular and Molecular Medicine on October 15, 2020
  • Demonstrated that the non-psychoactive reagent in cannabis (CBD) can significantly reduce the lung damage induced by cytokine storms

Herzliya, Israel and Calgary, Alberta–(October 23, 2020) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan“), is pleased to announce the recent publication of two scientific articles supporting Innocan’s approach of using CBD-Loaded Exosomes (CLX) for the treatment of COVID-19. The first paper entitled, “Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patients” published in the Journal of Stem Cell Research & Therapy on October 15, 2020 outlined that mesenchymal stem cells (MSCs) and their exosomes have potential therapeutic functions in the handling of COVID-19. Specifically, the study demonstrated that exosomes have the ability to enhance alveolar fluid clearance and promote epithelial and endothelial recovery through secretion of protective factors.

The second paper entitled, “Cannabidiol (CBD) modulation of apelin in acute respiratory distress syndrome” published in the Journal of Cellular and Molecular Medicine on October 15, 2020, demonstrated that the non-psychoactive reagent in cannabis (CBD) can significantly reduce the lung damage induced by cytokine storms (which is a physiological reaction in humans and other animals in which the innate immune system causes an uncontrolled and excessive release of pro-inflammatory signaling molecules called cytokines) caused by COVID-19.

Innocan Israel, a wholly owned subsidiary of the Company, together with Tel Aviv University Prof. Daniel Offen and his team, are developing a revolutionary combined therapy using MSC-driven Exosome-based loaded with CBD. The new combination is designed to target COVID-19 and neurodegenerative diseases.

Through their potential synergistic anti-inflammatory effect, CBD-Loaded Exosomes hold the potential of helping the body fight against the COVID-19 virus’s direct damage and its cytokine storm. This product is planned to act as a “guided missile” to the infected tissues, as the Exosomes migrate to Inflamed zones that are carrying CBD.

Prof. Offen added: “The recent publications which support our unique approach is exciting. The potential synergistic effect of CBD and Exosomes is of great potential for COVID-19 and other diseases known for local inflammation that causes destruction. We are doing our best efforts to accelerate the development and to potentially offer a new approach for the COVID-19 treatment”.

About Innocan

Innocan Israel is a pharmaceutical tech company that focuses on the development of several drug delivery platforms containing CBD. Innocan Israel and Ramot at Tel Aviv University, are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the COVID-19 Coronavirus using CBD. CBD-Loaded Exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

Innocan Israel signed a worldwide exclusive license agreement with Yissum, the commercial arm of The Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection. Innocan Israel plans, together with Professor Berenholtz Head of the Laboratory of Membrane and Liposome Research of The Hebrew University of Jerusalem, to test the liposome platform on several potential indications. Innocan Israel is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for the relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan Israel each have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

Innocan Pharma Corporation
Iris Bincovich, CEO
+972-54-3012842
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable

Tags: , , , , , , , , , ,
Posted in All Recent Posts, Featured, Innocan Pharma Corporation | Comments Off on Innocan Pharma $INNO.ca Announces the Publication of Two Studies Supporting Its CLX Therapy for COVID-19 Infected Lung Cells $IN.ca $AXIM $LABS $CRDL.ca $TBP.ca

Innocan Pharma’s $INNO.ca Clinical Study in the US Indicates that More than 90% of Participants Experienced Pain Reduction After Using Innocan’s Relief &Go OTC Pain Relief Spray $CGC.ca $APHA $OVAT.ca $KHRN.ca

Posted by AGORACOM-JC at 4:11 PM on Monday, October 19th, 2020
Innocan-Blog
  • Study indicates that more than 90 % of participants experienced reduction in pain after using Innocan’s Relief & Go OTC Pain Relief Spray
  • The clinical study was conducted on 18 participants: 10 participants with chronic pain and 8 participants with pain associated with other circumstances
  • Most participants described their pain before using the spray as throbbing and uncomfortable and a few described their pain as distressing

Herzliya, Israel and Calgary, Alberta–(October 19, 2020) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan“), is pleased to announce today a Clinical Study, conducted by Dr. Josef Geldwert and the Center for Podiatric Care & Sports Medicine in New York. The study indicates that more than 90 % of participants experienced reduction in pain after using Innocan’s Relief & Go OTC Pain Relief Spray. The clinical study was conducted on 18 participants: 10 participants with chronic pain and 8 participants with pain associated with other circumstances. Most participants described their pain before using the spray as throbbing and uncomfortable and a few described their pain as distressing. The location of the pain varied from the upper extremities of the back to the lower extremities and feet.

After 20 minutes 83% of participants noticed immediate improvement in pain.
After 60 minutes 95% of participants noted relief from pain.
After 24 hours almost 90% noted relief from pain.

15 of the 18 participants would recommend the Relief and GO pain spray.


Relief and GO Pain Spray

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6922/66309_f493f3f5d4ab1931_002full.jpg

The Center for Podiatric Care & Sports Medicine in New York specializes in treating chronic problems resulting from sports injuries and active lifestyles.

Dr. Josef Geldwert has over 40 years of experience in foot surgery, biomechanics, and sports injuries. In addition, he has been a medical authority to numerous professional sports teams.

In addition, Dr. Geldwert serves as advisor on Innocan Pharma’s Scientific Advisory committee.

Innocan Pharma’s Relief & Go Pain Relief Spray is a patent pending Over-The-Counter solution designed to relieve pain by combing three different mechanisms in one product: Menthol and Methyl salicylate with CBD and Magnesium.

Dr. Josef Geldwert stated, “I have been following up with patients who I have been seeing for foot and ankle related problems that have been using Relief and Go Pain Relief Spray, and their responses have been positive. I am impressed by how well patients have been doing with a non-prescriptive OTC pain relief spray.”

“We are thrilled that our clinical test yielded such promising results,” says Ms. Iris Bincovich, Chief Executive Officer of Innocan, “Our unique approach and deep experience is exemplified in these impressive results that I’m certain are only the beginning.”

About Innocan

Innocan Israel, a wholly owned subsidiary of the Company, is a pharmaceutical tech company that focuses on the development of several drug delivery platforms containing CBD. Innocan Israel and Ramot at Tel Aviv University, are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 Corona Virus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

Innocan Israel signed a worldwide exclusive license agreement with Yissum, the commercial arm of The Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection. Innocan Israel plans, together with Professor Berenholtz Head of the Laboratory of Membrane and Liposome Research of The Hebrew University of Jerusalem, to test the liposome platform on several potential indications. Innocan Israel is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for the relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan Israel each have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

Innocan Pharma Corporation
Iris Bincovich, CEO
+972-54-3012842
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable

Tags: , , , , , , , , , , , ,
Posted in All Recent Posts, Featured, Innocan Pharma Corporation | Comments Off on Innocan Pharma’s $INNO.ca Clinical Study in the US Indicates that More than 90% of Participants Experienced Pain Reduction After Using Innocan’s Relief &Go OTC Pain Relief Spray $CGC.ca $APHA $OVAT.ca $KHRN.ca

Innocan Pharma’s $INNO.ca Cosmetic Clinical Study Indicates a 90% Wrinkle Reduction After Using Its SHIR(TM) Premium #CBD Facial Serum $CGC.ca $APHA $OVAT.ca $KHRN.ca

Posted by AGORACOM-JC at 4:15 PM on Thursday, October 15th, 2020
Innocan-Blog
  • Completed a cosmetic clinical study on 20 volunteers that presented a 90 – 95% facial skin wrinkle reduction after using its SHIR ™ Premium CBD Facial Serum
  • “Achieving these amazing results is due to the combination of active ingredients with a specific amount of CBD, result in a tremendous facial skin improvement. The SHIR Beauty & Science skincare brand combines the benefits of CBD’s most effective ingredients into an innovative formula which is leading to visible fast-acting results…” stated Iris Bincovich, Chief Executive Officer of Innocan.”

Herzliya, Israel and Calgary, Alberta–( October 15, 2020) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan“), is pleased to announce today that it has completed a cosmetic clinical study on 20 volunteers that presented a 90 – 95% facial skin wrinkle reduction after using its SHIR ™ Premium CBD Facial Serum. 

The following are the results of the application of the SHIR – Innocan Pharma Facial Serum with 300 mg of Cannabidiol (“CBD”) after 28 days of using the serum twice a day:

The percentage of the subjectsThe subjects considered after using the SHIR™ Premium Facial Serum for 28 days
90%The skin with less wrinkles
95%With finer expression lines
100%The anti-wrinkles effect is the most appreciated product’s effect
90%A more even skin tone
80%A depigmenting effect
85%The skin was more moisturized
90%Evaluated the product as good to very good

Before and After pictures:



Figure1‏ Subject‏ ID‏ ‏126 eye contour wrinkles‏ ‏3D before‏ picture
To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6922/66022_fe9690d2e4cdc93e_002full.jpg


Figure2‏ Subject‏ ID‏ ‏126 eye contour wrinkles‏ ‏3D after 28 days picture
To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6922/66022_fe9690d2e4cdc93e_003full.jpg

“Achieving these amazing results is due to the combination of active ingredients with a specific amount of CBD, result in a tremendous facial skin improvement. The SHIR Beauty & Science skincare brand combines the benefits of CBD’s most effective ingredients into an innovative formula which is leading to visible fast-acting results. Each ingredient was carefully chosen to provide a synergistic effect, working in harmony with each other. The high satisfaction of the volunteers enrolled at the study may indicate a high potential of the targeted market to welcome SHIR Beauty & Science skincare line of products and accelerate InnoCan market penetration,” stated Iris Bincovich, Chief Executive Officer of Innocan.”

The clinical study was conducted by UPTEC, Science and Technology Park of the University of Porto, Portugal which is an independent lab. The findings of the clinical study were consistent with the main principles of ICH GCP, Helsinki declaration and Portuguese legal requirements.

About Innocan

Innocan Israel, a wholly owned subsidiary of the Company, is a pharmaceutical tech company that focuses on the development of several drug delivery platforms containing CBD. Innocan Israel and Ramot at Tel Aviv University, are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 Corona Virus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

Innocan Israel signed a worldwide exclusive license agreement with Yissum, the commercial arm of The Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection. Innocan Israel plans, together with Professor Berenholtz Head of the Laboratory of Membrane and Liposome Research of The Hebrew University of Jerusalem, to test the liposome platform on several potential indications. Innocan Israel is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for the relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan Israel each have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

Innocan Pharma Corporation
Iris Bincovich, CEO
+972-54-3012842
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Tags: , , , , , , , , , , , ,
Posted in All Recent Posts, Innocan Pharma Corporation | Comments Off on Innocan Pharma’s $INNO.ca Cosmetic Clinical Study Indicates a 90% Wrinkle Reduction After Using Its SHIR(TM) Premium #CBD Facial Serum $CGC.ca $APHA $OVAT.ca $KHRN.ca

REMINDER: Innocan Pharma $INNO.ca to Provide Corporate Update via Livestream Video Today at 10am EST $IN.ca $AXIM $LABS $CRDL.ca $TBP.ca

Posted by AGORACOM-JC at 8:25 AM on Wednesday, October 14th, 2020
Innocan-Blog

The company will provide a corporate update to the investment community and shareholders through a YouTube livestream video on today at 10:00am EST.

The update will include a corporate presentation by Innocan’s CEO Iris Bincovich describing the key research milestones achieved by the company to date, and a scientific review by Innocan’s Scientific Advisor Professor Daniel Offen.

The YouTube livestream video will be available through livestream.innocanpharma.com

Hub On AGORACOM / Read Recent Release…

Innocan Achieves Major Milestone in Developing Its Unique CBD-Loaded Liposome Platform Technology for Injectable CBD

  • Study on mice demonstrated a prolonged release of Cannabidiol into the blood for at least three weeks after one administration
  • Conducted based on Innocan’s licensed CBD loaded liposome platform technology for injectable CBD
  • Conducted on over 35 mice and found significant amounts of CBD in the mice’s blood 21 days after they were injected with a single injection of liposomal CBD using Innocan’s CBD loaded LPT
  • Results are substantial when comparing the oral or smoking administration of CBD, in which CBD was found in the blood of mice only for a period of up to 36 hours after one administration
  • Results open the door for future experiments to prove the lack of toxicity and beneficial therapeutic efficacy of the formulations.

Tags: , , , , , , , , , , , ,
Posted in Featured, Innocan Pharma Corporation | Comments Off on REMINDER: Innocan Pharma $INNO.ca to Provide Corporate Update via Livestream Video Today at 10am EST $IN.ca $AXIM $LABS $CRDL.ca $TBP.ca

Innocan $INNO.ca Achieves Major Milestone in Developing Its Unique CBD-Loaded Liposome Platform Technology for Injectable #CBD $WEED.ca $CL.ca $HEXO.ca $RWB.ca

Posted by AGORACOM-JC at 4:11 PM on Friday, October 9th, 2020
Innocan-Blog
  • Study on mice demonstrated a prolonged release of Cannabidiol into the blood for at least three weeks after one administration
  • Conducted based on Innocan’s licensed CBD loaded liposome platform technology for injectable CBD
  • Conducted on over 35 mice and found significant amounts of CBD in the mice’s blood 21 days after they were injected with a single injection of liposomal CBD using Innocan’s CBD loaded LPT
  • Results are substantial when comparing the oral or smoking administration of CBD, in which CBD was found in the blood of mice only for a period of up to 36 hours after one administration
  • Results open the door for future experiments to prove the lack of toxicity and beneficial therapeutic efficacy of the formulations.

Herzliya, Israel and Calgary, Alberta–(October 9, 2020) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan“), is pleased to announce today that an animal study on mice, demonstrated a prolonged release of Cannabidiol (“CBD”) into the blood for at least three weeks after one administration. This study was conducted by The Hebrew University of Jerusalem, Israel based on Innocan’s licensed CBD loaded liposome platform technology (“LPT”) for injectable CBD.

The study which was led by Dr. Ahuva Cern, Senior Researcher in the lab of Prof. Berenholz, was conducted in The Hebrew University of Jerusalem laboratories on over 35 mice and found significant amounts of CBD in the mice’s blood 21 days after they were injected with a single injection of liposomal CBD using Innocan’s CBD loaded LPT.

These results are substantial when comparing the oral or smoking administration of CBD, in which CBD was found in the blood of mice only for a period of up to 36 hours after one administration.

These results open the door for future experiments to prove the lack of toxicity and beneficial therapeutic efficacy of the formulations.

Innocan Israel, a wholly owned subsidiary of the Company, has entered into a worldwide exclusive research and license agreement with Yissum Research and Development Company (“Yissum“), the commercial arm of The Hebrew University of Jerusalem in respect of the design, preparation, characterization and evaluation of hydrogels containing CBD (or other cannabinoids) loaded liposomes. The research and development is led by Professor Chezy Barenholz, head of the Membrane and Liposome research department at The Hebrew University, which was the inventor of over 55 patent families, two of which underlie Doxil® – an FDA approved drug for breast cancer treatment. This unique technology platform may be implemented for several indications such as epilepsy, pain relief, and different inflammation and central nervous system disorders. A patent was filed on this technology on October 7, 2019.

Professor Chezy Berenholz stated, ” I believe that the results of this animal study, showing the prolonged release of CBD into the blood stream is an extremely important major milestone. This may open a wide range of clinical applications which may allow for the maintenance of a certain level of CBD in the blood for a longer period of time which may also lead to improved patient’s compliance. If successful, this technology may be beneficial for various additional indications.”

Iris Bincovich, Innocan’s CEO, added, “As variety of studies demonstrates the effectiveness of cannabinoids in the treatment of various CNS conditions, this has the potential to address indication such as Epilepsy.”

About Innocan

Innocan Israel is a pharmaceutical tech company that focuses on the development of several drug delivery platforms containing CBD. Innocan Israel and Ramot at Tel Aviv University, are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the COVID-19 coronavirus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

Innocan Israel signed a worldwide exclusive license agreement with Yissum, the commercial arm of The Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection. Innocan Israel plans, together with Professor Berenholz, to test the liposome platform on several potential indications. Innocan Israel is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for the relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan Israel each have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+972-54-3012842
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Tags: , , , , , , ,
Posted in All Recent Posts, Featured, Innocan Pharma Corporation | Comments Off on Innocan $INNO.ca Achieves Major Milestone in Developing Its Unique CBD-Loaded Liposome Platform Technology for Injectable #CBD $WEED.ca $CL.ca $HEXO.ca $RWB.ca

Innocan Pharma $INNO.ca to Provide a Corporate Update via Livestream Video $WEED.ca $CL.ca $HEXO.ca $RWB.ca

Posted by AGORACOM-JC at 4:10 PM on Thursday, October 8th, 2020
Innocan-Blog
  • Will provide a corporate update to the investors community and shareholders through a YouTube livestream video on October 14, 2020 at 10:00am EST.
  • update will include a corporate presentation by Innocan’s CEO Iris Bincovich describing the key research milestones achieved by the company to date, and a scientific review by Innocan’s Scientific Advisor Professor Daniel Offen.

Herzliya, Israel and Calgary, Alberta–(October 8, 2020) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan“), is pleased to announce that it will provide a corporate update to the investors community and shareholders through a YouTube livestream video on October 14, 2020 at 10:00am EST.

The update will include a corporate presentation by Innocan’s CEO Iris Bincovich describing the key research milestones achieved by the company to date, and a scientific review by Innocan’s Scientific Advisor Professor Daniel Offen.

The YouTube livestream video will be available through livestream.innocanpharma.com

About Innocan

The Company is a pharmaceutical tech company that focuses on the development of several drug delivery platforms containing Cannabidoil (“CBD”). Innocan Israel, a wholly owned subsidiary of the Company, and Ramot at Tel Aviv University, are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 Corona Virus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

Innocan Israel signed a worldwide exclusive license agreement with Yissum, the commercial arm of The Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection. Innocan Israel plans, together with Professor Berenholtz Head of the Laboratory of Membrane and Liposome Research of The Hebrew University, to test the liposome platform on several potential indications. Innocan Israel is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for the relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan Israel each have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+972-54-3012842
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Tags: , , , , , , , ,
Posted in Innocan Pharma Corporation | Comments Off on Innocan Pharma $INNO.ca to Provide a Corporate Update via Livestream Video $WEED.ca $CL.ca $HEXO.ca $RWB.ca

8 Small Cap #Cannabis Companies That Will Lead The Next Growth Cycle For The $97 Billion Market By 2026 $AVCN.ca $CBDT.ca $HBOR.ca $HOLL.ca $INNO.ca $SPDR.ca $TBI.ca $TCAN.ca

Posted by AGORACOM-JC at 3:39 PM on Thursday, October 8th, 2020

Despite the collapse of marijuana and cannabis related stocks in the last 18 months, there is no denying that Cannabis related products are going to go through a paradigm shifting, parabolic growth stage around the world over this decade for the following reasons:

  1. Cannabis legalization is gaining momentum around the world.
  2. Momentum is primarily driven by the realization that cannabis may have a range of medicinal, therapeutic and wellness applications.
  3. It is the most widely cultivated, consumed and trafficked drug worldwide (United Nations Office on Drugs and Crime).

So what is this going to translate into?

The global cannabis market size was valued at $US 10.6 Billion in 2018 and is projected to reach $97.5 Billion by the end of 2026, a CAGR of 32.92% (Fortune Business Insights)

WHY WILL THIS TIME BE DIFFERENT?

Big promises, big IR budgets, big hype …. Big Letdown.

That pretty much sums up the last cycle of Cannabis related companies that focused on speed, stories and stock prices rather than the one simple but important thing they should have been doing – building a real business.

Investors will remember that the same thing happened during the dot-com era.  As with the cannabis collapse over the last 18 months, what followed back in 2000 was a long period of mourning in which many investors had sworn off tech stocks, just as they have with cannabis stocks today.

But it wasn’t long until tech investors dusted themselves off and realized tech was here to stay – but this time they were only going to focus on real companies with real businesses.  What we got was Amazon, Google, Linkedin, Facebook and then the rest was history.

The same thing is about to happen to the Cannabis sector

Meet the 8 new horsemen of the next leadership group that are firing on all cylinders (in alphabetical order).

Avicanna (AVCN :TSX) (AVCN : OTCQX) ( 0NN: FSE) is a vertically-integrated biopharmaceutical company developing and commercializing various cannabinoid-based products for the global marketplace.

When we say vertically integrated, we mean it. Avicanna has 4 fully operating divisions to address the entire market for Cannabis products as follows:

1.  The company has a full line of high end CBD based skin care products serving the consumer retail segment with Canadian distribution through Medical Cannabis by Shoppers, as well as global distribution later this year.  These are the only known CBD cosmetics backed by clinical trials.

2.  Avicanna’s superior medical cannabis line also features products distributed through Medical Cannabis by Shoppers, the online arm of Canada’s largest drugstore chain. In addition, the company recently received certification and authorization for the sale of pharmaceutical cannabinoid products with medical prescriptions in Colombia.

3.  Avicanna also hosts a full pipeline of Pharmaceuticals in various stages of trials to address Dermatology, Psychiatry, Neurology, Pain and Oncology. Three of the company’s products are already as far as phase 2.

AND… if that is not enough …

4.  Avicanna’s Colombian cultivation division hosts 500,000 Sq ft of low cost and USDA certified organic Cannabis Cultivation. The company recently Made History As The First Ever Export Of Feminized Hemp Seeds From Colombia To The United States. 7,000,000 Seeds For $380,000, with an additional 75,000,000 Seeds Available For Export In Several Pending Transactions.

For more information about the company, please check out the Avicanna HUB on AGORACOM.

Empower (CBDT: CSE) (EPWCF:OTCQB) (8EC:Frankfurt) is a vertically integrated, multi-state operator of medical clinics with a database of over 165,000 patients, a database that almost every medical cannabis and CBD company would kill for … but then these numbers recently came in for the first two quarters to further cement Empower as a leader:

PatientVisits

  • Q1 + 377% To 5,717
  • Q2 + 56% To 6,696

Revenues $USD

  • Q1 + 416% To $790,000 (NO COVID)
  • Q2 + 56% To $923.000

TOTAL Q1 AND Q2

  • REVENUE                 $1.7M vs $745K         = + 130%
  • PATIENTS                 12,400 vs 5,500           = + 125%
  • NET LOSS                 $920K vs 1.85M         = – 50% 

Empower has now delivered growth in 4 successive financial reports (Q4, FY 2019, Q1 and Q2), so it is safe to say that superstar CEO Steve McAuley can officially claim victory on the turnaround he inherited in 2019. 

BONUS – The Company’s physician staffed clinics have are also generating significant revenue and growth from the COVID-19 pandemic as follows: 

  • Increased CBD treatments from patients suffering increased anxiety;
  • Testing for individuals and families
  • Testing for local businesses and employees 
  • Testing for enterprise level organizations across the country 
  • Acquisition of an 8,000 sq ft lab in Dallas that can process 4,000 COVID-19 tests per day
    • At the lowest price of $USD 80 per test and operating on just 1,000 tests per day, the clinic would deliver $USD 80,000 in revenue PER DAY

Oh, and did we mention that CEO Steven McAuley is Six Sigma certified under the quality initiative of legendary GE (General Electric) Chairman Jack Welch? We’ve never seen a Six Sigma certified CEO in the Canadian small cap markets. Never.  Which explains how McAuley has been able to guide Empower Clinics through the most disruptive retail environment in recent history and turn it into significant growth.

For more information about the company, please check out the Empower HUB on AGORACOM.

Harborside (HBOR: CSE), (HSDEF: OTCQX) has generated over $400,000,000 (NOT a typo) since its inception in 2006.  We thought that would get your attention.

What Do They Do?

HBOR is a California-focused, vertically integrated, fully licensed cannabis company with its business consisting of three primary segments:

1. Retail Dispensaries

2. Wholesale

3. Cultivation and Processing

HIGHLIGHTS

  • Founded in 2006. One of the oldest and most respected cannabis retailers in California
  • Awarded one of the first six medical cannabis licenses in the USA
  • Operations have generated over $400M in cumulative sales since inception
  • Retail operations command 3% of California’s entire retail market
  • 2020 Financials (Q1 +  Q2)

○       Revenues         $30,800,000

○       Gross Profit     $14,000,000

○       EBITDA            $1,100,000

  • Expected to generate approximately $62M – $65M in sales in 2020
  • Operate California’s only drive-through dispensary 
  • Over 1,300 customers per day in Q2
  • Oakland dispensary is one of the largest retail cannabis locations in the world
  • 2020E Guidance
    • ~$44M Retail Revenue
    •   ~$21M Wholesale Revenue
    • ~$62M – ~65M Total Revenue

For more information about the company, please check out the Harborside Inc  hub on AGORACOM.

Hollister Biosciences Inc. (HOLL:CSE) (HSTRF:OTC) (HOB: FRANKFURT) is a multi-state cannabis company with products in 230 dispensaries throughout California and over 80 dispensaries throughout Arizona, translating into the following great success:

  • Revenues $USD
    • Q1 +317%  YoY to $862,000
    • Q2 +3685% YoY to  $8,500,000
  • TOTAL Q1 AND Q2
    • REVENUE                 $9.4M vs $428K     = + 2096%
    • GROSS PROFIT        $1.2M vs ($133K)   = + 1002%

In addition to organic sales, Hollister has several high-level partnerships that demonstrate how trusted the Company is within the industry, including:

Hollister is also the creator of California’s most hash-infused pre-roll HashBone

For more information about the company, please check out the Hollister Biosciences Inc. hub on AGORACOM.

Innocan Pharma Corporation (INNO: CSE) (IP4:FSE) is developing the pharmaceutical guided missile to defeat coronavirus lung infections. The company specializes in the development of new drug platforms which combine unique properties of Cannabinoids.

3 Fully Operating Divisions For Investor Diversification

Innocan has 3 fully operating divisions to address the market for Cannabis products.  As a Cannabis investor, why limit yourself to a Company with just one specialty, when Innocan offers you exposure to both the exploding world of cannabis pharma, as well as, a portfolio of patent-pending and launch ready consumer health products.

  1.  PHARMACEUTICAL – THE GUIDED MISSILE – Revolutionary technology targeting lungs infected with coronavirus or other viral infections.
  2. CONSUMER RETAIL – DERMA COSMETICS – A premium derma cosmetics brand, manufacturing has commenced with distribution agreements in place.
  3. OVER THE COUNTER (OTC) PRODUCTS FOR PAIN RELIEF – patent-pending CBD pain relief brand received FDA technical validation.

Global Manufacturing / Distribution Agreements

  • Endless Sky Inc. a Canadian large scale Cannabis extractor (Manufacturing and Distribution – Canada)
  • Swiss CBD provider Cloud 9 Switzerland LLC (Distribution – Italy and Switzerland)
  • Active Therapeutics Ltd of Lancashire, United Kingdom (Distribution – UK and Ireland markets)

Superior Management Team

In the small cap world, the jockey(s) that drive the horse are just as important as the horse itself.  The InnoCan Leadership Group Is Incomparable In The Small Cap World, Comprised Of Leading Israeli Pharmaceutical Executives including:

  • Executive Chairman (Ron Mayron) was the CEO Of Teva Israel, one of the largest generic pharmaceutical companies in the world
  • Co-Founder & VP Business Development (Yoram Drucker) was the Founder of 2 NASDAQ Companies (Pluristem & Brainstorm)
  • Chief Technology Officer (Nir Avram) is a former member of the pharma innovation team at Perrigo, producer of OTC consumer goods and specialty pharma.
  • Chief Executive Officer (Iris Bincovich) has a proven track record in opening global markets, having managed hundreds of successful transactions in OTC, cosmetics and dermatology.

Together they have built one of the most formidable teams in the small cap cannabis world

For more information about the company, please check out the Innocan Pharma Corporation hub on AGORACOM.

Spyder Cannabis Inc. (SPDR :TSXV) is a Cannabis, Vape and CBD retailer with three retail business units.

  1. SALE OF CANNABIS PRODUCTS – The Company has TWO cannabis dispensaries currently in operation. The first being a location in Calgary, Alberta and the second in Niagara Falls. Both dispensaries are located in busy commercial hubs. The management team is currently evaluating several additional locations in both Alberta and Ontario where it intends to expand the Spyder Cannabis brand’s footprint.
  2. SALE OF HEMP CBD (US) Company is also pursuing the sale of Hemp based CBD products from locations in the USA.
  3. SMOKING CESSATION PRODUCTS IN ONTARIO The company sells electronic cigarettes, E-juice and accessories for the “vape” business from five Canadian retail locations; Woodbridge, Scarborough, Pickering, Niagara Falls and Burlington, Ontario. Spyder has established itself as a savvy retailer.

For more information about the company, please check out the Spyder Cannabis  hub on AGORACOM.

Thoughtful Brands, Inc. (TBI: CSE)( 1WZ1: FWB)( PEMTF: OTCQB) is a global natural health products and eCommerce technology company that is operating at full throttle. 

  • Acquired eCommerce retailers with combined total sales of approximately $29,000,000 with an EBITDA of approximately 12.5%.
  • Current customer base of over 200,000 customers with additional leads of over 600,000 potential new customers
  • Enhanced eCommernce solution through Unified Funding’s software which facilitated over $350 million in consumer transactions (CAD $93.8 million) in 2019 from more than one million paying customers.
  •  Low-cost production will be vertically integrated into retail brands to achieve up to 20x margin increase.

We’ll let these revenue numbers speak for themselves.

  • August 2020 CAD $3,809,000
  • July 2020 CAD $2,340,000
  • June 2020 CAD $2,712,000

The above represents an increase of 19%, over the same period in 2019.

QUARTERLY REVENUE $CAD

  • Q1 $7,600,000 Growth
  • Q2  $12,800,000 Growth 

TOTAL Q1 AND Q2

  • REVENUE  $20,400,000
  •  GROSS PROFIT  $2,154,357

The company has its sights set on European expansion through a joint venture with Franchise Cannabis Corp. The company will now sell and market Franchise-manufactured CBD, hemp and cosmetic products in the European Union, Switzerland, Norway and the UK, utilizing its eCommerce platform.

The company also completed acquisition of Verrian, which owns and operates a 110,000-square foot pharmaceutical manufacturing facility in Radebuel, Germany. This acquisition will assist the company in tapping into the burgeoning market for psychedelics as Verrian specializes in developing psychedelic derived medicines for treatments for addictions, including opioids and alcohol.

For more information about the company, please check out the Thoughtful Brands hub on AGORACOM. 

TransCanna (TCAN:CSE) (TH8:FSE) owns a 196,000 square foot cannabis Facility, the largest known fully licensed cannabis facility in California.

  • CAD $24.9M  Revenue Run Rate from 10,000 sq.ft  test facility
  • CAD $90M Annual Revenue expected from first full year of production at Fully Licensed Daly Street Facility.
  • Acquired two California companies,
  • High-end award winning edible producer Soldaze
    • Premium indoor cultivator and distributer Lyfted Farms
  • Lyfted Farms products sold in select Cookies Locations – The most recognizable name in high-end Cannabis.
  • 2019 California Cannabis sales over $3B, industry currently fragmented 
  • Direct to dispensary model, cutting out the middleman

 REVENUES  $CAD

  • Q1  $906,000
  • Q2  $4,300,000

 TOTAL Q1 AND Q2

  • REVENUE     $5,206,000    
  • GROSS MARGIN $1,920,000

For more information about the company, please check out the TransCanna hub on AGORACOM.

Thanks for reading and discovering these great small cap cannabis companies.  Please be sure to visit the AGORACOM Small Cap Cannabis Gateway often to stay up to date with new companies at:

https://agoracom.com/portal/Small-Cap-Marijuana-Cannabis-Stocks

Tags: , , , , , , , ,
Posted in AGORACOM Small Cap Stocks For Investment, All Recent Posts, Avicanna Inc., Empower Clinics Inc., Featured, Hollister Biosciences, Innocan Pharma Corporation, Spyder Cannabis Inc., Thoughtful Brands Inc., TransCanna Holdings Inc. | Comments Off on 8 Small Cap #Cannabis Companies That Will Lead The Next Growth Cycle For The $97 Billion Market By 2026 $AVCN.ca $CBDT.ca $HBOR.ca $HOLL.ca $INNO.ca $SPDR.ca $TBI.ca $TCAN.ca

MEDIA: How Richard Carleton Is Leading The Cannabis Revolution At The #CSE – #Innocan Pharma $INNO.ca $WEED.ca $CL.ca $HEXO.ca $RWB.ca

Posted by AGORACOM-JC at 9:37 AM on Monday, October 5th, 2020

InnoCan Pharma (INNO:CSE) Is A Pharmaceutical Company That Specializes In The Development Of New Drug Platforms Which Combine Unique Properties of Cannabinoids. InnoCan has 3 fully operating divisions to address the market for Cannabis products.  As a Cannabis investor, why limit yourself to a Company with just one specialty, when InnoCan offers you exposure to both the exploding world of cannabis pharma, as well as, a portfolio of patent-pending and launch ready consumer health products. Learn more.

Innocan-Blog

How Richard Carleton Is Leading The Cannabis Revolution At The CSE

Cannabis has emerged as a viable commodity for international trade, and the Canadian Stock Exchange is leading the charge.

  • A great example of this InnoCan Pharma (CSE: INNO, FSE: IP4), a specialty pharmaceutical company, developing products that harness the unique properties of Cannabinoids combined with smart delivery formulations
  • InnoCan just recently announced a worldwide exclusive license agreement with the Hebrew University of Jerusalem to develop a first-of-its-kind CBD drug delivery platform based on liposomes
  • This Patent-Pending platform is based on a unique-controlled liposome-release method to be administrated, for the first time, by injection, turning Pharma Cannabinoids-based Medicines to an ever-accessible injectable drug.

The growing cannabis market

As the cannabis industry continues to advance, more and more companies are moving to get their stocks listed on Canada Securities Exchange. Cannabis is no longer just a plant. The debate on its legality, decriminalization, health benefits, among others, are now the main focus of attention. Cannabis has emerged as a viable commodity for international trade, and raw material for consumption, with several companies listed on the stock market and shareholders who speculate on its rise or fall according to news of its legalization in more corners.

A great example of this InnoCan Pharma (CSE: INNO, FSE: IP4), a specialty pharmaceutical company, developing products that harness the unique properties of Cannabinoids combined with smart delivery formulations. InnoCan just recently announced a worldwide exclusive license agreement with the Hebrew University of Jerusalem to develop a first-of-its-kind CBD drug delivery platform based on liposomes. This Patent-Pending platform is based on a unique-controlled liposome-release method to be administrated, for the first time, by injection, turning Pharma Cannabinoids-based Medicines to an ever-accessible injectable drug.

Although the debate will always be present, more and more countries have chosen to decriminalize and even promote the use of cannabis, especially for medicinal purposes. The likes of Germany, Argentina, Italy, Canada, etc already allow the use of CBD derivatives to treat health problems, always under medical prescription, but often even facilitating their access to patients.

Cannabis for recreational activities is now an emerging discourse, and borders that seemed immovable a while ago have been crossed. Canada passed a regulation in 2018 that made it one of the few countries that fully allowed recreational consumption and the first of the G-8.

It thus joined Uruguay, a country that has always had a fairly permissive position. And the Netherlands, which despite the fame of its cannabis sale in coffee shops, has not changed its regulation in recent years (The Netherlands does not allow cultivation for self-consumption). As well as Mexico, who in a wide debate in recent years, have legalized marijuana for medical use. In the United States, almost 30 of its states have opened the door to medicinal consumption, and about 10 of them, including California, to recreational use.

The growth of the marijuana-related market has exploded in recent years and according to GlobeNewswire, “The global legal marijuana market size is expected to reach USD 73.6 billion by 2027.” This includes medicinal, recreational, and derivatives.

Furthermore, “It is anticipated to expand at a CAGR of 18.1% during the forecast period. The increasing legalization of cannabis for medical as well as adult-use is expected to promote growth. Based on type, the medical segment held the leading revenue share of 71% in 2019, owing to the growing adoption of cannabis as a pharmaceutical product for treating severe medical conditions, such as cancer, arthritis, and Parkinson’s disease, and Alzheimer’s disease among other neurological conditions. Moreover, an increasing need for pain management therapies along with the growing disease burden of chronic pain among elders is expected to boost the product demand.”

In this context, in recent years numerous companies, especially in the pharmaceutical industry, have begun to fully immerse themselves in this buoyant market with the expectation that over time it will become increasingly legal in more countries. Most of these companies are Canadian, and they have emerged in the glow of the country’s decriminalization momentum.

Some are dedicated to distribution for recreational consumption, those that lean more to the medical side, and those that are specializing in derivatives. Several things unite them: they are all Canadian for their reference in legalization, they are all growing, and a lot of them have successfully been listed on the stock market.

Canadian Securities Exchange (CSE)

Without a doubt, the Canadian Securities Exchange (CSE) has played a vital role in strengthening the marijuana-related market in Canada. Led by a visionary CEO, Richard Carleton, it has emerged as one of the pillars of cannabis investment in the country. Exchange operators have critically guided affairs, bringing about the availability of a variety of investment options for cannabis investors.

The CSE is Canada’s fastest-growing stock exchange. With more than 600 listings and a cumulative market capitalization of approximately C$23 billion, the Exchange continues to attract entrepreneurial companies that are looking for the most efficient path to the North American capital markets. With the help of the Canada Securities Exchange, Canadian companies can choose to test the waters outside Canada, particularly in the United States, as long as they can allay the fears of shareholders. Presently, cannabis is illegal on a federal level in the USA, however, it is legal for medical and recreational purposes in a good number of states.

The Canadian Securities Exchange (CSE) is the go-to platform for cannabis companies who are still developing. It offers much-needed exposure for the growth of these emerging companies, while also giving established organizations, such as multi-state operators in the US, a chance to gain a competitive advantage in the global market.

According to Richard Carleton, “It is always gratifying to see companies capitalizing on opportunities in the public market to pursue their vision for growth. The CSE has a mandate to facilitate entrepreneurial activity such as this.”

Looking at the medical aspect, he further believes that large and small companies have complementary roles in the pharmaceutical industry. Start-up companies play an important role in conducting early research and development in identifying new drug therapies. History shows that a lot of value creation happens in this space before the drugs are taken through clinical trials and ultimately brought to the market by the pharma giants and are prescribed to patients worldwide. In addition, regardless of their size, pharma companies need to have exceptional technical and logistical talent to develop a drug and move it through regulated trials.

Presently, there is a tremendous amount of effort in the pursuit of therapies and vaccines for COVID-19. This recent activity is a good reminder of how powerful the public markets are at organizing capital to solve real-world issues. You can be sure that whatever health challenge society is presented with next, the market will be here to find solutions.

https://seekingalpha.com/instablog/52407514-dennz54/5504073-how-richard-carleton-is-leading-cannabis-revolution-cse

Tags: , , , , , , , ,
Posted in All Recent Posts, Featured, Innocan Pharma Corporation | Comments Off on MEDIA: How Richard Carleton Is Leading The Cannabis Revolution At The #CSE – #Innocan Pharma $INNO.ca $WEED.ca $CL.ca $HEXO.ca $RWB.ca

CLIENT FEATURE: Innocan Pharma $INNO.ca Developing The Pharmaceutical Guided Missile To Defeat #Coronavirus Lung Infections $WEED.ca $CL.ca $HEXO.ca $RWB.ca

Posted by AGORACOM-JC at 5:36 PM on Friday, September 25th, 2020
Innocan-Blog

(INNO:CSE)

InnoCan Pharma Is A Pharmaceutical Company That Specializes In The Development Of New Drug Platforms Which Combine Unique Properties of Cannabinoids

WHY INNOCAN?

InnoCan has 3 fully operating divisions to address the market for Cannabis products.  As a Cannabis investor, why limit yourself to a Company with just one specialty, when InnoCan offers you exposure to both the exploding world of cannabis pharma, as well as, a portfolio of patent-pending and launch ready consumer health products.

PHARMACEUTICAL – THE GUIDED MISSILE

  • Revolutionary Technology Targeting Lungs Infected  With Coronavirus or other viral infections 
    • Done By Combining CBD with Stem Cell Particles (Exosomes)
    • Research & Licensing Agreement with Tel Aviv University
  • Developing CLX, The ICBM Ballistic Missile Of Coronavirus Lung Infections
  • Separate breakthrough delivery and control release technology that enables the injection of CBD.

CONSUMER RETAIL – DERMA COSMETICS 

Completed Successful Cosmetic Clinical Studies Demonstrating the Efficacy of Its SHIR(TM) CBD Premium Facial Serum on Skin Hydration

  • A Premium Derma Cosmetics Brand
  • Containing Highly Concentrated Ingredients Formulated with CBD
  • Manufacturing & Supply Agreements – Europe and United States
  • Manufacturing Has Commenced For 9 Products As Of Q2 2020
  • Distribution Agreements – United Kingdom and Ireland

OVER THE COUNTER (OTC) PRODUCTS FOR PAIN RELIEF

  • Patent-Pending CBD Pain Relief Brand
  • Versions Include Spray, Roll-On and Cream
  • Relief & Go Spray – First Product Being Manufactured
    • FDA Technical Validation
    • FDA Approval To Commence Marketing In The United States
  •   Manufacturing Commencement
    • New Jersey (United States Market)
    • Portugal (Asia and Europe Markets)
  • Sales Commenced In H2 2020 during September

SEEING IS BELIEVING

FULL DISCLOSURE: Innocan Pharma is an advertising client of AGORA Internet Relations Corp.

Tags: , , , , , , , , ,
Posted in AGORACOM Client Feature, All Recent Posts, Featured, Innocan Pharma Corporation | Comments Off on CLIENT FEATURE: Innocan Pharma $INNO.ca Developing The Pharmaceutical Guided Missile To Defeat #Coronavirus Lung Infections $WEED.ca $CL.ca $HEXO.ca $RWB.ca

« Older Entries
Newer Entries »